kines; B-cell leukemia Allogeneic bone marrow or blood stem cell transplantation (BMT) is indicated for effective treatment of malignant hematologic disorders and possibly metastatic solid tumors resistant to conventional anticancer modalities. [1] [2] [3] BMT provides the therapeutic benefits of graft-versus-leukemia (GVL) or graft-versus-tumor (GVT) effects mediated by immunocompetent donor lymphocytes reacting against residual tumor cells of host origin that are frequently resistant to chemoradiotherapy. 3 The therapeutic advantages of GVL or GVT reactions are often negated by graftversus-host disease (GVHD). 2, 3 The main cause of morbidity and mortality following BMT. Removal of donor T lymphocytes from the stem cell inoculum, the only effective way of preventing GVHD, is often associated with an increased incidence of both graft rejection and leukemia relapse. 2 GVL effects independent of GVHD have been documented previously, 2, [4] [5] [6] suggesting, therefore, that retention of GVL effects while preventing GVHD may be possible by administering nonalloreactive or tumor-specific T cells capable of selectively recognizing and killing leukemic cells of host origin. To achieve this goal, GVHD effector cells would have to be eliminated or downregulated, thus tolerizing the donor against host antigens while retaining or more effectively upregulating putative GVL effector cells. We chose different procedures to immunize C57BL/6 (H- These observations may offer a simple approach for developing new ways of maximizing GVL effects while minimizing GVHD in patients with malignant lymphoid disorders. 2-4 months were purchased from the Hebrew UniversityHadassah Medical School Animal Facility, Jerusalem, Israel. All the animals were kept under standard conditions in top filtered cages and given acidified water (pH 2.7) and food ad libitum. Cages, sawdust and water bottles were autoclaved once a week.
Materials and methods

Mice
Murine BCL1
BCL1, a B-cell leukemia/lymphoma of BALB origin first described by Slavin and Strober, 7, 8 was maintained in vivo by serial passage in BALB recipients. Inoculation of BALB mice with 10-100 BCL1 cells results in typical B-cell leukemia/lymphoma characterized by extreme splenomegaly (50 Â normal size by weight or cell number), extreme peripheral blood lymphocytosis (up to 500 000/mm 3 ) and death of 100% of the recipients. BCL1 also causes lethal leukemia in F 1 recipients. However, due to partial hybrid resistance, a larger inoculum is required to induce leukemia in 100% of the recipients (41000 BCL1/recipient). 8 
Immunization of donor mice
For testing GVL and GVHD across MHC barriers, B6 mice serving as spleen cell donors were divided into three groups.
Group 1: B6 mice immunized with spleen cells obtained from BCL1-bearing mice (30 Â 10 6 cells/mouse/immunization).
Group 2: B6 mice immunized with spleen cells obtained from normal BALB mice (30 Â 10 6 cells/mouse/immunization).
Group 3: Normal untreated B6 mice receiving no immunization.
Spleen cells from these donors were used to induce GVL effects in (BALB/c Â C57BL/6) F 1 recipients inoculated with 10 4 BCL1 cells. To test GVL and GVHD across minor histocompatibility barriers, the same protocol was used to immunize B10.D2 mice serving as donors of spleen cells: Group 1 was immunized with BCL1 spleen cells; Group 2 was immunized with normal BALB spleen cells; and Group 3 was left untreated. Spleen cells from these donors were used to induce GVL effects in BALB recipients inoculated with 2 Â 10 3 BCL1 cells. Spleen cells used for immunization were injected intraperitoneally (i.p) twice: on days À20 and À10 prior to transplantation.
Total body irradiation
The mice were conditioned by total body irradiation (TBI) with a single dose of 400 cGy delivered by a linear accelerator (Varian Climac 6 X) at a source to skin distance of 80 cm, and a dose rate of 170 cGy/min. 
Immunotherapy of BCL1 by transplantation of spleen cells across MHC and mHgs
Assay for chimerism
Chimerism was documented by determining the percentage of host-or donor-type cells in spleen or blood samples by an in vitro complement-dependent microcytoxicity assay, using specific alloantisera and rabbit complement. Specific alloantisera (BALB anti-B6 and B6 anti-BALB) were prepared by cross-immunization with full-thickness skin allografts, followed by six i.p. injections of 30 Â 10 6 donor spleen cells at intervals of 1-2 weeks. Mice were bled and the sera were stored at À701C until used. Chimerism was confirmed by typing spleen or peripheral blood lymphocytes with both alloantisera and rabbit complement. Lymphocytes obtained from F 1 recipients were lysed with both anti-BALB and anti-B6 antisera, whereas lymphocytes obtained from B6-F 1 chimeras were lysed with anti-B6 only. Percent chimerism was calculated as follows: % donor type B6 cells ¼ (% cells lysed by anti-B6 antiserum) À% cells lysed by anti-BALB/c antiserum À% cells lysed by complement alone.
Monitoring of GVHD
Recipients were monitored for survival and clinical signs of GVHD (ruffled fur, diarrhea), measurable weight loss and survival. At the time of adoptive transfer, samples of liver and lung sections were obtained from each mouse and examined microscopically for histologic evidence of GVHD and leukemia. Histological preparations were analyzed by an independent pathologist (LS) on a double blind-basis.
Cytokine assays
Spleen cells from immune donors were assayed 20 days after immunization. Spleen cells were obtained from recipients 3 weeks post transplantation. Spleen cells were washed in phosphate-buffered saline (PBS) and resuspended in RPMI1640 medium supplemented with 10% fetal bovine serum (GIBCO, Grand Island, NY, USA), 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mm l-glutamine (Biological Industries, Beit Haemek, Israel). Spleen cells were then incubated in 24-well flat bottom plates (Greiner Labortechnik, Germany) at a concentration of 1 Â 10 6 cells/ml/well, with or without 2.5 mg/ml Concanavalin A (ConA) (BioMakor, Rehovot, Israel), at 371C in a 5% CO 2 humidified air incubator. Cell supernatants were harvested after 24 and 48 h of incubation, cleared by centrifugation (12 000 g, 10 min) and stored at À801C until assayed. The levels of IFN-g, IL-2, IL-I0 and IL-12 were determined in culture supernatants, using a ''sandwich'' ELISA technique. ELISA reagents were purchased from Pharmingen, San Diego, CA, USA and used according to the manufacturer's instructions: 96-well flat-bottom plates (Nunc Maxisorb, Denmark) were coated with anticytokine capture antibody diluted in borate buffer, pH 8.2, and incubated overnight at 41C. The plates were washed twice with PBS-0.2% Tween and nonspecific binding was blocked by adding PBS containing 2% BSA for 2 h at room temperature. Supernatant was then added to duplicate wells in parallel with serial dilutions of a recombinant cytokine standard and the plates were incubated overnight at 41C. The plates were washed 4 Â with PBS-0.2% Tween, the respective biotinylated anticytokine detecting antibody was added to all the wells and they were incubated for 45 min at room temperature. After washing the plates 6 Â with PBS-0.2% Tween, streptavidinalkaline phosphatase was added for 30 min at room temperature. Plates were then washed 8 Â with PBS-0.2%Tween and phosphatase substrate plus hydrogen peroxide (10 ml H 2 O 2 per 10 ml substrate) were added to all the wells, at room temperature (10-30 min). The color reaction was terminated by the addition of 50 ml 1 M NaOH per well. The optical density was read immediately by an ELISA reader (Organon Tecknika, USA) at 405 nm. A standard curve was generated to determine the cytokine concentration in each sample.
9,10
Detection of residual BCL1 cells by adoptive transfer experiments An in vivo assay was used to detect residual BCL1 in the experimental mice as previously published. 11 A total of 10 5 lymphocytes obtained from a pool of spleen cells from each experimental group were adoptively transferred to untreated secondary BALB recipients. The development of leukemia was monitored by weekly peripheral blood lymphocyte (PBL) counts, spleen enlargement and survival. Blood samples (20 ml) were obtained by weekly venipuncture using heparinized glass capillaries, and counted in a hemocytometer after lysis of the red blood cells in 2% acetic acid. Development of leukemia (PBL 420 000/mm 3 ) in secondary recipients served as an indicator of minimal residual disease in the primary recipients. We have previously shown that by in vivo adoptive transfer, a residual load of 1-10 cells may be detected. 8 Similar results can be confirmed with BCL1-specific PCR although PCR is not more sensitive. 12 
Statistical methods
The statistical significance of the results was calculated by the Kaplan-Meier survival curve test. Cytokine data were analyzed by the Mann-Whitney test. 13 
Results
Immune donor spleen cells induce greater GVL effects across the MHC than do unstimulated spleen cells, independent of GVHD GVL effects were induced by i.v. injection of BCL1 cells and B6 spleen cells on day +1 into F 1 recipients conditioned on day 0 with sublethal TBI (400 cGy). The mice were divided into four groups (6-10 mice/group): (1) Figure 1b shows that 100% (40/40) of the secondary recipients inoculated with spleen cells obtained from Group 1 remained leukemia-free for 4120 days; 63% (25/40) of the secondary BALB recipients inoculated with spleen cells obtained from Group 2 remained leukemia-free for 4120 days; and 68% (27/40) of the secondary BALB recipients inoculated with spleen cells obtained from Group 3 remained leukemia-free for 4120 days. In contrast, all 40 secondary BALB recipients of the spleen cells obtained from the control group died of leukemia within 30 days. Blood lymphocytes taken from F 1 recipients included 46-56% donor-type cells, confirming engraftment (Table 1) .
Upon comparing the degree of GVHD in each group, we observed that all the mice lost weight within the first 2 weeks of transplantation ( Figure 1c ). Therefore, early GVHD cannot be excluded. It is difficult to judge whether the weight loss was related to true GVHD, the conditioning or both. However, if the animals survived this period, 75% of the mice in Group 1 and 48% in Group 2 recovered, regained weight and remained active with no clinical evidence of GVHD for 4120 days. All animals in Group 3 died within 75 (median 56) days with typical signs of acute GVHD. The body weight curves of the individual mice in each group, an objective indicator of the severity of GVHD, are shown in Figure 1c . 
-----------------------------------------------------------
Cytokine profile in correlation with GVHD and GVL phenomena
The cytokine profile of donor spleen cells was examined in all the experimental and control mice. As shown in Table 2 , the levels of IFN-g secreted by spleen cells of B6 mice immunized (across the MHC) with BCL1 and spleen cells of B6 mice immunized with normal BALB cells were much higher than those observed in normal B6 spleen cells (P ¼ 0.007 and 0.002, respectively). The levels of IL-2 secreted by spleen cells of B6 mice immunized with BCL1 and spleen cells of B6 mice immunized with normal BALB cells were also higher than those observed in normal cells (P ¼ 0.001 and 0.001, respectively). The levels of IL-10 secreted by spleen cells of B6 immunized with normal BALB cells and spleen cells of B6 mice immunized with BCL1 were higher than those in spleen cells of normal B6 mice (P ¼ 0.007 and 0.0675, respectively). There were no significant differences between the levels of IFN-g, IL-2 and IL-10 in spleen cells of B6 mice immunized with BCL1 and spleen cells of B6 mice immunized with BALB. There were no significant differences in the levels of TNF-a, IL-4 and IL-12 among the three experimental groups (data not shown). Table 3 shows the cytokine level in supernatants of spleen cells from B10.D2 mice immunized (across mHgs) with BCL1 or BALB spleen cells. The levels of IFN-g, IL-2, IL-10 and IL-12 secreted by spleen cells of B10.D2 mice immunized with BCL1 were higher than those secreted by spleen cells of normal B10.D2 spleen cells (P ¼ 0.0053). Similarly, cytokine levels secreted by spleen cells from B10.D2 mice immunized with BALB were also significantly elevated (P ¼ 0.0033) ( Table 3 ). There were no significant differences in the levels of IFN-g, IL-2, IL-10 and IL-12 in spleen cells of B10.D2 mice immunized with BCL1 and in spleen cells of B10.D2 immunized with BALB. Table 4 shows the levels of IFN-g in supernatants of spleen cells obtained from recipient F 1 mice 3 weeks post transplantation. The level of IFN-g secreted by spleen cells of F 1 mice treated with spleen cells of B6 immunized with BCL1 was three-to six-fold less than that of F 1 recipients treated with spleen cells of B6 immunized with normal BALB or of F 1 recipients treated with spleen cells of normal B6 donors in both 24-and 48-h cultures stimulated with Table 2 Cytokine levels in supernatants of spleen cells from C57BL/6 donors following different immunization protocols a Cells used for immunization INF-g (pg/ml) P IL-2 (pg/ml) P IL-10 (pg/ml) P There was no significant difference between the two immunized groups.
Table 3
Cytokine levels in supernatants of spleen cells from B10.D2 donor mice after different immunization protocols a Cells used for immunization IFN-g (pg/ml) P IL-2 (pg/ml) P IL-10 (pg/ml) P IL-12 (pg/ml) P ConA in vitro. However, these differences were not significant.
Discussion
In the experiments described here, mice were inoculated with a constant number (2 Â 10 3 - 10 4 ) of BCL1 cells, a murine leukemia/lymphoma that resembles lymphocytic leukemia/lymphoma in man, in order to mimic minimal residual disease after high-dose chemotherapy or bone marrow transplantation. GVL effects were induced with naı¨ve, nonspecific and specifically immune donor spleen cells across MHC or mHgs barriers. GVL effects as well as the incidence of GVHD were compared between recipients of allogeneic cells immunized with leukemic cells, normal spleen cells of host origin or nonimmune donor-type cells. Our data indicate that donor spleen cells obtained from mice immunized against host-type tumor cells, and to a lesser extent normal host alloantigens, can induce better therapeutic GVL effects with less lethal GVHD across MHC and mHgs histocompatibility barriers. Eradication of BCL1 was reconfirmed by adoptive-transfer experiments in secondary BALB mice to avoid possible masking of GVL effects by lethal GVHD or by induction of tumor dormancy, which may result in disease-free survival despite the continuous presence of clonogenic BCL1 cells, a phenomenon previously observed in BCL1. [14] [15] [16] Failure to develop leukemia in secondary recipients is an absolute indication of the elimination of all BCL1 cells in the primary recipient. 5 However, failure to develop leukemia in primary recipients, even if lethal GVHD is prevented, need not necessarily prove elimination of all clonogenic BCL1 cells, since existing tumor cells may be actively suppressed or dormant, rather than eliminated, as previously documented. [14] [15] [16] [17] Elimination of BCL1 cells in the primary recipients inoculated with B6 or in B10.D2 mice immunized against BCL1 as early as 3 weeks following allogeneic cell therapy clearly indicates that GVL effects might be induced prior to overt clinical manifestations of GVHD in the primary recipients. Interestingly, our earlier work using the same model showed that GVL effects could be achieved within 2-3 weeks, 5 whereas death from GVHD usually occurred at a later stage, as we have also shown here. These observations imply that temporary engraftment of MHCor mHgs-mismatched allogeneic effector cells for X3 weeks may be sufficient to induce beneficial GVL effects, certainly against minimal residual disease, without the need for permanent residence of allogeneic effector cells, which in clinical practice may cause severe GVHD, especially across MHC barriers. Induction of GVL effects with no clinically overt GVHD was previously reported in mice 4 and man, 2 especially in recipients with minimal residual disease. 18 Documentation of GVL effects independent of GVHD in our present study implies that tolerized donor T cells can specifically recognize tumor antigens or, alternatively, be tolerized against host alloantigens and not against tumor cells bearing similar host-type MHC or mHgs determinants, thus retaining their GVL potential. Alternatively, GVL and GVHD could be mediated by different T-cell clones 19 including NK cells that may react against tumor cells but not against normal cells.
20 Lymphocyte activation may also result in IL-2-dependent activation of NK cells 15, 21 or alloreactive NK cells. 24 Another possible explanation is that tumor cells are more sensitive to allogeneic effector T cells than normal target cells or that the tumor cells fail to induce apoptosis of alloreactive T cells, whereas normal allogeneic cells theoretically may have this capacity. The simplest explanation is that the antitumor effects might be sufficient to kill minimal residual cells in parallel with subclinical GVHD. Regardless of the mechanism, the feasibility of inducing curative GVL effects by donor lymphocytes with no clinical evidence of GVHD was previously reported in BCL1-leukemia 4, 5 as well as in other murine tumor models 6 and in man. 25, 26 The observation that BCL1-immune cells were more effective than BALB-immune donor cells against BCL1 is not surprising. However, the finding that these cells can immunize the donor against tumor cells of host origin while responding minimally to host alloantigens should be further investigated. Zeis et al 24 previously demonstrated effective eradication of residual disease by administration of leukemia-specific T cells after BMT. 24 It is conceivable that the tumor cells present their tumor-associated cellsurface antigens, the immunoglobulin idiotype in the case of B-cell malignancy, with costimulatory molecules, which is an effective way of inducing antitumor immunity. 24 It was indeed documented that BCL1 cells carry cell-surface B7 molecules, considered to be the most important costimulatory components, which interact with CD28 of the responding T cells. 25 Improved induction of unresponsiveness to host alloantigens by tumor cells that may have a smaller number of cell-surface MHC molecules compared with that of normal host cells may therefore explain their reduced GVHD potential. Amplification of antitumor responses without augmentation or even downregulation of antihost responses following immunization of donors with tumor cells of host origin is not exclusively unique to BCL1. We have previously documented a similar phenomenon in BALB/c mice inoculated with metastatic breast cancer cells treated with naı¨ve, alloimmune or tumorimmune donors (B10.D2) which also features improved graft-versus-tumor-effects independently of GVHD. Lower or unaltered antihost alloreactivity was previously reported following immunization of donors with host alloantigen, suggesting that in the context of BMT the incidence of acute and/or chronic GVHD in irradiated mice can be downregulated. 25, [27] [28] [29] The cytokine profile may also help to characterize the mechanism of GVL effects compared with those of GVHD across MHC or mHgs barriers, and provide an interesting alternative explanation. Increased IL-10 levels of donor cells may be associated with downregulation of GVHD, suggesting that specific immunization of donor animals might have resulted in a Th 1 -Th 2 cytokine shift, 30, 31 however, in addition to elevated IL-10, IFN-g and IL-12 secretions were elevated too, suggesting a somewhat atypical cytokine shift, or a mixed population of Th 1 -Th 2 shift with additional tumor-reactive Th 1 -type cells. This shift could explain why these cells have a diminished GVHD capacity while augmenting GVL. We previously showed that immunization with BCL1 cells results in antileukemia immunity. 25 These data imply the existence of specific antitumor effects against BCL1-specific cell-surface determinants, absent from normal BALB. Furthermore, allogeneic B10.D2 donor cells can mount a specific response against BCL1 cells that is distinct from the response against normal mHgs expressed in normal cells. Such effects are most likely mediated primarily, though not necessarily exclusively, by CD8 + cytoxic T lymphocytes, as was shown by us previously. 35 Our present findings indicate that induction of protective immunity independent of GVHD may depend on tumor-specific recognition, which may be induced by Th 2 -type donor cells and will not be as effective against normal host-type cells. Alternatively, Th 2 -type cells may be capable of downregulating GVHD reactivity. Our results support the findings of Okubo et al, 33, 34 who suggested that polarized type 2 alloreactive CD4 + and CD8 + donor T cells may fail to induce acute GVHD. Alternatively, the process of immunization under our experimental conditions may have resulted in induction of antihost unresponsiveness by inactivation of alloreactive cells, also known as activation-induced apoptosis, without affecting antileukemia reactivity. The possible involvement of double negative (natural killer) T cells was also suggested by Sefriouri et al 35 following injection of host-type bone marrow cells in chimeras established across mHgs. 35 Earlier studies with effector cells of GVHD have indicated a unique phenotype and different cytokine profiles of GVHD effector cells, CD8 + cytotoxic cells, which play a major role in GVHD, and cells induced during alloactivation, with particular attention to the CD8 + phenotype and immunoregulatory cytokines. [36] [37] [38] [39] Our present results and earlier data obtained in other laboratories suggest that activated alloreactive cells may alter their function depending on the cytokine profile, which may change during cell activation, depending on the circumstances and experimental conditions. In the future, these observations may prove helpful in controlling cell function by regulating the cytokine cascade of the activated cells through intentional selection of Th1 vs Th2 phenotype activation pathways.
A comparable approach would involve in vitro activation procedures to avoid the need for donor sensitization by inoculation with irradiated tumor cells, which, although safe, may be unacceptable to institutional review boards. The feasibility of augmenting GVL while avoiding or controlling GVHD could lead to improved therapeutic approaches for eradicating leukemia while reducing procedure-related morbidity and mortality due to uncontrolled GVHD. Engraftment with reduced GVHD by prior donor immunization may also provide a better opportunity for allogeneic cell therapy postgrafting after induction of complete or mixed chimerism and host-versus-graft tolerance following myeloablative 18 or nonmyeloablative conditioning. 40 Although our results need further confirmation via additional tumor-donor combinations, the process involved in upregulating GVL effects while downregulating GVHD should be further investigated as an important potential tool for immunotherapy of hematologic malignancies resistant to chemoradiotherapy. The therapeutic potential of allogeneic cell therapy in leukemia has been confirmed by many transplant centers. 41 More recently, allogeneic cell therapy inducible with donor lymphocyte infusion following nonmyeloablative stem cell transplantation has been suggested as a potential tool for controlling metastatic solid tumors in experimental animals 42, 43 and man. 44 In summary, immunization of donor mice with host tumor antigens or normal host alloantigens is likely to increase the GVL potential of effector cells in conjunction with BMT, while possibly reducing their detrimental GVHD effects. It remains to be determined if this immunization procedure can be effectively used in clinical practice to improve the outcome of BMT while avoiding or downregulating GVHD.
